Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease

Pojsakorn Danpanichkul¹, Donghee Kim², Benjamin Nah³, Karn Wijarnpreecha^{4

5

6}, Suthat Liangpunsakul^{7

8

9}

Affiliations

¹ Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
³ Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
⁵ Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
⁶ BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁸ Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
⁹ Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.

Pojsakorn Danpanichkul et al. Clin Mol Hepatol. 2025 Jul.

. 2025 Jul;31(3):e273-e276.

doi: 10.3350/cmh.2025.0474. Epub 2025 May 27.

Pojsakorn Danpanichkul¹, Donghee Kim², Benjamin Nah³, Karn Wijarnpreecha^{4

5

6}, Suthat Liangpunsakul^{7

8

9}

¹ Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
³ Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
⁵ Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
⁶ BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁸ Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
⁹ Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.

No abstract available

Keywords: Alcohol-associated hepatitis; Alcohol-related liver disease; Pharmacotherapy; Statin.

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

1. Danpanichkul P, Díaz LA, Suparan K, Tothanarungroj P, Sirimangklanurak S, Auttapracha T, et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021. Clin Mol Hepatol. 2025;31:525–547. - PMC - PubMed
1. Alvarado-Tapias E, Pose E, Gratacós-Ginès J, Clemente-Sánchez A, López-Pelayo H, Bataller R. Alcohol-associated liver disease: Natural history, management and novel targeted therapies. Clin Mol Hepatol. 2025;31(Suppl):S112–S133. - PMC - PubMed
1. Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021;8:687585. - PMC - PubMed
1. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force. JAMA. 2016;316:2008–2024. - PubMed
1. El Said NO, El Wakeel LM, Khorshid H, Darweesh EAG, Ahmed MA. Impact of lipophilic vs hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: A prospective comparative randomized study. Br J Clin Pharmacol. 2021;87:2855–2866. - PubMed